Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gemcitabine + Lacutamab + Oxaliplatin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Lacutamab | IPH-4102|IPH 4102|IPH4102 | Lacutamab (IPH4102) is a monoclonal antibody that targets KIR3DL2, which potentially results in increased anti-tumor immune response against KIR3DL2-expressing tumor cells, and reduced tumor growth (PMID: 25361998, PMID: 31253572). | ||
Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Active, not recruiting | USA | POL | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04984837 | Phase II | Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin | Study of Lacutamab in Peripheral T-cell Lymphoma | Recruiting | FRA | ESP | DEU | BEL | 0 |